Investor Presentaiton

Investor presentation ADA 2019 Comparison of post-hoc analyses of SUSTAIN 6, LEADER and REWIND for prior and no prior MI/stroke subgroups Slide 8 Outcome Prior MI/stroke No. events* Sema Pbo Hazard ratio (95% CI) Interaction p-value SUSTAIN 6 With 66 88 0.76 (0.55 1.05) 3-point MACE 0.75 Without 42 58 0.70 (0.47 1.04) Outcome Prior MI/stroke No. events* Lira Pbo Hazard ratio (95% CI) LEADER With 322 372 0.84 (0.72 0.97) 3-point MACE 0.56 Without 286 322 0.89 (0.76 1.05) Prior No. events* Outcome MI/stroke Dula Pbo Hazard ratio (95% CI) REWIND With 196 236 0.79 (0.66 0.96) 3-point MACE 0.18 Without 396 423 0.93 (0.81 1.07) With prior MI/stroke Without prior MI/stroke 1.0 2.0 *First events Lira N=1,865; Sema N=673; Dula N=1,028 Pbo N 1,827; Pbo N=694; Pbo N=1,007 Lira N=2803; Sema N=975; Dula N=3,896 0.4 Pbo N=2845; Pbo N=955; Pbo N=3,920 Poulter N et al. Abstract 86477, presented at the European Society of Cardiology Congress, Barcelona, 28 August 2017 Leiter L et al. 2019. Cardiovascular Risk Reduction with only once weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovasc Diabeto 18:73. https://doi.org/10.1186/s12933-019-0871-8; Supplement appendix to: Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomized placebo-controlled trial. Lancet 2019; published online June 10. CI: confidence interval; CV: cardiovascular; MI: myocardial infarction; PYO: patient-years of observation; Lira: Liraglutide; Sema: Semaglutide; Dula: dulaglutide Pbo: Placebo novo nordisk

View entire presentation